North Bergen, New Jersey — August 18, 2025 — Leads & Copy — Apollo Biowellness, Inc. (OTC Pink: KOAN) has been approved to file on OTCIQ and is in final negotiations with an Israeli-based Bio-Tech and Biologics manufacturer, listed on NASDAQ, for co-development of a shelf-stable biologic cosmetic, Ceilo Skin Care, planned for launch in the 4th Quarter of 2025 via retail, direct-to-consumer, and e-commerce platforms.
The company is also in talks with a large aesthetic company in the Laser Energy Devices business for a potential merger to create a combination therapy company selling Biologics and Aesthetic devices.
Apollo plans to launch a first-of-its-kind pet and veterinarian biologic using exosomes and placental products for pets, sold exclusively through licensed veterinarians, clinicians, and pet professionals before the end of Q3 2025. The product will use 100% natural biologic products to treat arthritis, joint, inflammation, and skin issues in pets, including topical and injectable therapeutics.
Apollo is working with debt and convertible note holders to restructure, refinance, or convert positions to a preferred class of equity to coordinate financing for growth plans over the next 12 months.
James W. Zimbler, President and CEO, anticipates an exciting next 12 months for the company.
James W. Zimbler, President/CEO/Director, info@evolutionarybiologics.com, 631-806-1420
Source: Apollo Biowellness, Inc.
Source: Apollo Biowellness, Inc.
